FDAFDA · Food and drugs·Recall number D-0213-2023
GLYCERIN/LIDOCAINE HCL/EPINEPHRINE 31%(V/V)/0.17%/0.00017% (10ML VIALS); GLYCERIN/LIDOCAINE HCL/EPINEPHRINE 48.7%(W/V)/0.67%/0.00067% (10ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
Published February 1, 2023 · Recall initiated: December 22, 2022
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
What to do
Voluntary: Firm initiated · Telephone
Recall details
- Manufacturer
- Pharmacy Innovations
- Distributor
- Nationwide in the USA
- Lot
- t20221116@36 t20221117@11
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Sell products like this?
Recalert watches your whole catalog for recalls like this one, automatically.